Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJin Xu

About this trial

This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.

Eligibility criteria

Qualifiers

Sign informed consent;

Aged 18-75 years (inclusive);

Histologically or cytologically confirmed pancreatic cancer;

Unresectable locally advanced or metastatic pancreatic cancer, as determined by the investigator;

Disqualifiers

The subject has any known active autoimmune disease;

Subjects have any complications requiring systemic treatment with corticosteroids such as prednisone (> 10mg/ day) or have used immunosuppressive drugs within 14 days prior to initial administration;

Subjects received tumor vaccines or other immune-activating antitumor drugs (such as interferon, interleukin, thymosin, or immune cell therapy) within 1 month prior to initial administration;

Subjects are participating in another clinical trial or have received a drug intervention from another clinical trial within 4 weeks prior to the first dose;

Trial design

Treatments tested in this trial

  • Adebrelimab
  • AG

Treatment groups

46 Participants
are divided into 1 treatment group

Sponsors and collaborators

Jin Xu

Lead sponsor

Fudan University

Sponsor institution